(Q40899271)

24 September 2017

1 reference

title

Cognitive function in schizophrenia--do neuroleptics make a difference? (English)

1 reference

24 September 2017

0 references

Mortimer AM

1

1 reference

24 September 2017

language of work or name

English

0 references

publication date

1 April 1997

1 reference

Pharmacology, Biochemistry and Behavior

24 September 2017

published in

1 reference

24 September 2017

volume

56

1 reference

24 September 2017

issue

4

1 reference

24 September 2017

page(s)

789-795

1 reference

Hypofrontality in neuroleptic-naive patients and in patients with chronic schizophrenia. Assessment with xenon 133 single-photon emission computed tomography and the Tower of London

24 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2896%2900425-X

7 January 2021

Intellectual deficits in first-episode schizophrenia: evidence for progressive deterioration

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2896%2900425-X

7 January 2021

Neuropsychological deficit in schizophrenic subtypes: paranoid, nonparanoid, and schizoaffective subgroups

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2896%2900425-X

7 January 2021

Performance and its measurement

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2896%2900425-X

7 January 2021

The comparative efficacy and long-term effect of clozapine treatment on neuropsychological test performance.

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2896%2900425-X

7 January 2021

Neuropsychological assessment of schizophrenic patients during a psychotic episode: persistent cognitive deficit?

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2896%2900425-X

7 January 2021

Neuroleptics: effects on neuropsychological function in chronic schizophrenic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2896%2900425-X

7 January 2021

Memory in schizophrenia: what is impaired and what is preserved?

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2896%2900425-X

7 January 2021

Sensorimotor and cognitive performance of schizophrenic inpatients treated with haloperidol, flupenthixol, or clozapine

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2896%2900425-X

7 January 2021

Neuroleptic drug effects on cognitive function in schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2896%2900425-X

7 January 2021

Cognitive impairment as a target for pharmacological treatment in schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2896%2900425-X

7 January 2021

Mechanisms of action of clozapine in the treatment of neuroleptic-resistant and neuroleptic-intolerant schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2896%2900425-X

7 January 2021

Memory impairment in schizophrenia--a comparison with that observed in the Alcoholic Korsakoff syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2896%2900425-X

7 January 2021

Experiences of alien control in schizophrenia reflect a disorder in the central monitoring of action.

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2896%2900425-X

7 January 2021

Akinesia, tardive dysmentia, and frontal lobe disorder in schizophrenia.

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2896%2900425-X

7 January 2021

Contrasts between patients with affective disorders and patients with schizophrenia on a neuropsychological test battery.

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2896%2900425-X

7 January 2021

The effect of clozapine on cognition and psychiatric symptoms in patients with schizophrenia.

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2896%2900425-X

7 January 2021

Course of schizophrenia: neuropsychological evidence for a static encephalopathy

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2896%2900425-X

7 January 2021

Learning and memory in monozygotic twins discordant for schizophrenia.

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2896%2900425-X

7 January 2021

Further evidence for dementia of the prefrontal type in schizophrenia? A controlled study of teaching the Wisconsin Card Sorting Test

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2896%2900425-X

7 January 2021

What are the functional consequences of neurocognitive deficits in schizophrenia?

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2896%2900425-X

7 January 2021

Improvement in cognitive functions and psychiatric symptoms in treatment-refractory schizophrenic patients receiving clozapine.

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2896%2900425-X

7 January 2021

Neuropsychological deficits in schizophrenics. Relationship to age, chronicity, and dementia.

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2896%2900425-X

7 January 2021

Neuropsychological functioning of first-episode schizophreniform patients

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2896%2900425-X

7 January 2021

Is there cognitive decline in schizophrenia? A cross-sectional study

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2896%2900425-X

7 January 2021

The new atypical antipsychotics. A lack of extrapyramidal side-effects and new routes in schizophrenia research

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2896%2900425-X

7 January 2021

The effect of neuroleptics on cognitive and psychomotor function

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2896%2900425-X

7 January 2021

The effect of neuroleptics on cognitive and psychomotor function. A preliminary study in healthy volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2896%2900425-X

7 January 2021

A controlled study of 99mTc-HMPAO single-photon emission imaging in chronic schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2896%2900425-X

7 January 2021

Age disorientation in chronic schizophrenia is associated with global intellectual impairment.

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2896%2900425-X

7 January 2021

Schizophrenic syndromes and frontal lobe performance.

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2896%2900425-X

7 January 2021

Semantic memory is impaired in schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2896%2900425-X

7 January 2021

Central monitoring deficiency and schizophrenic symptoms.

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2896%2900425-X

7 January 2021

Cognitive inflexibility and pre-frontal dysfunction in schizophrenia and mania

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2896%2900425-X

7 January 2021

The disabilities of chronic schizophrenia--their nature and the factors contributing to their development.

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2896%2900425-X

7 January 2021

The clinical relevance of an auditory attention task (PAT) in a longitudinal study of chronic schizophrenia, with placebo substitution for chlorpromazine

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2896%2900425-X

7 January 2021

Severe cognitive impairment in elderly schizophrenic patients: a clinicopathological study.

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2896%2900425-X

7 January 2021

Psychosurgery and the Porteus Maze Tests: review and reanalysis of data

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2896%2900425-X

7 January 2021

Comparative placebo-controlled pharmacodynamic studies with zotepine and clozapine utilizing pharmaco-EEG and psychometry.

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2896%2900425-X

7 January 2021

Neuropsychological deficits in neuroleptic naive patients with first-episode schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2896%2900425-X

7 January 2021

Neuropsychological performance in chronic schizophrenia in response to neuroleptic dose reduction

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2896%2900425-X

7 January 2021

Evaluation of the stability of neuropsychological functioning after acute episodes of schizophrenia: One-year followup study

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2896%2900425-X

7 January 2021

Monoamines and abnormal behaviour. A multi-aminergic perspective

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2896%2900425-X

7 January 2021

Neuroleptic effects on neuropsychological test performance in schizophrenia.

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2896%2900425-X

7 January 2021

Physiologic dysfunction of dorsolateral prefrontal cortex in schizophrenia. I. Regional cerebral blood flow evidence

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2896%2900425-X

7 January 2021

Ordering thoughts on thought disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2896%2900425-X

7 January 2021

Relation of neuroleptic and anticholinergic medication to cognitive functions in schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2896%2900425-X

7 January 2021

10.1016/S0091-3057(96)00425-X

Identifiers

DOI

1 reference

24 September 2017

1 reference